

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors

Changhoon Yoo, MD
Min-Hee Ryu, MD, PhD
Jungmin Jo, MD, PhD
Inkeun Park, MD
Baek-Yeol Ryoo, MD, PhD
Yoon-Koo Kang, MD, PhD

Department of Oncology,
Asan Medical Center,
University of Ulsan College of Medicine,
Seoul, Korea

Correspondence: Yoon-Koo Kang, MD, PhD
Department of Oncology, Asan Medical Center,
University of Ulsan College of Medicine,
88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505,
Korea

Tel: 82-2-3010-3230

Fax: 82-2-3010-8772

E-mail: ykkang@amc.seoul.kr

Received January 9, 2015

Accepted May 12, 2015

Published Online June 22, 2015

Purpose

The incidence of gastrointestinal stromal tumors (GISTs) harboring platelet-derived growth factor receptor alpha (*PDGFRA*) mutations is low, therefore further investigation of the efficacy of imatinib in this subgroup was needed.

Materials and Methods

Patients with *PDGFRA*-mutant GISTs who received imatinib as primary therapy for advanced disease between January 2000 and June 2012 were identified from the GIST registry of Asan Medical Center, Seoul, Korea.

Results

KIT and *PDGFRA* genotyping in 823 patients identified 18 patients (2%) with *PDGFRA* mutations who were treated with first-line imatinib. Exon 18 D842V substitution, non-D842V exon 18 mutations, and exon 12 mutations were detected in nine (50%), four (22%), and five (28%) patients, respectively. Objective response rate differed significantly between patients with the D842V mutation and those with non-D842V mutations (0% [0/5] vs. 71% [5/7], $p=0.03$). In all patients, median progression-free survival (PFS) and overall survival (OS) was 24.8 months (95% confidence interval [CI], 0.0 to 57.2) and 51.2 months (95% CI, 37.1 to 65.3), respectively. Significantly, poorer PFS was observed for patients with D842V-mutant GISTs than those with non-D842V *PDGFRA*-mutant GISTs: median 3.8 months (95% CI, 1.4 to 6.3) versus 29.5 months (95% CI, 18.3 to 40.7) ($p < 0.001$). Patients with the D842V mutation had poorer OS than those with non-D842V *PDGFRA* mutations: median 25.2 months (95% CI, 12.7 to 37.8) versus 59.8 months (95% CI, 43.0 to 76.5) ($p=0.02$).

Conclusion

Imatinib is active against non-D842V *PDGFRA*-mutant GISTs, whereas GISTs harboring the D842V mutation are primarily resistant to imatinib.

Key words

Imatinib, Gastrointestinal stromal tumors,
Platelet-derived growth factor receptor alpha

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Most GISTs harbor activating mutations of the genes encoding *KIT* or platelet-derived growth factor receptor alpha (*PDGFRA*), resulting in the constitutive activation of protein tyrosine

kinase signaling [1]. *KIT* mutations occur in 70%-85% of GISTs and are most common in exon 11, followed by exon 9, whereas exon 13 and 17 mutations are rare. *PDGFRA* mutations are detected in 5%-15% of GISTs and are mutually exclusive to *KIT* mutations [2-4].

Imatinib (Glivec / Gleevec, Novartis Oncology, East Hanover, NJ) has shown remarkably enhanced efficacy over conventional chemotherapy and has become the standard

first-line treatment for patients with unresectable or metastatic GISTs [5-8]. Extensive correlative analyses have identified the types of *KIT* mutations associated with the efficacy of imatinib in GISTs [9-11]: with imatinib treatment patients with *KIT* exon 9 mutations show poorer outcomes than those with *KIT* exon 11 mutations.

The association between imatinib sensitivity and *PDGFRA* mutations was investigated in a subgroup of patients included in prospective clinical trials, and *in vitro* and *in vivo* studies reported association of the *PDGFRA* exon 18 D842V substitution with resistance to imatinib [9,10,12]. However, because of the low incidence of *PDGFRA* mutations in advanced GISTs, data on the activity of imatinib against *PDGFRA*-mutant GISTs were mostly obtained in a small number of patients.

A recent retrospective study conducted in Europe analyzed 55 patients with *PDGFRA*-mutant GISTs [13]. Although this study is the largest of its kind to date, additional data are still needed in order to improve our understanding of these types of mutations, particularly considering the small sample size of previous studies. Therefore, we retrospectively analyzed the efficacy of first-line imatinib in patients with advanced GISTs harboring *PDGFRA* mutations.

Materials and Methods

Patients with *PDGFRA*-mutant GISTs who received imatinib as primary therapy for advanced disease between January 2000 and June 2012 were identified from the GIST registry of Asan Medical Center, Seoul, Korea. Data were collected from both the registry and retrospectively by review of medical records. During imatinib treatment, all patients were monitored regularly for evaluation of response by computed tomography scan every 3 months. Magnetic resonance imaging or positron emission tomography was performed when necessary. Response was assessed according to the Response Evaluation Criteria in Solid Tumors ver. 1.0 with some modifications [14]. Lesions showing necrosis, despite their increased size, and new cystic lesions in the liver were not considered disease progression [15]. This study was approved by the Institutional Review Board of Asan Medical Center.

For mutational analyses of the *KIT* and *PDGFRA* genes, 10 μ m tumor sections were cut from formalin-fixed paraffin-embedded tissue samples. Genomic DNA was extracted from three sections using a DEXPAT kit (TaKaRa, Kyoto, Japan). Exons 9, 11, 13, and 17 of *KIT*, and exons 12 and 18 of *PDGFRA* were amplified by polymerase chain reaction

Table 1. Baseline patient characteristics

Characteristic	No. (%) (n=18)
Sex	
Male	11 (61)
Female	7 (39)
Age, median (range, yr)	58 (31-74)
Disease status	
Localized but unresectable	2 (11)
Recurrent	6 (33)
Initially metastatic	10 (56)
<i>KIT</i> expression	17 (94)
Type of <i>PDGFRA</i> mutation	
Exon 18 D842V substitution	9 (50)
Non-D842V exon 18 mutation	4 (22)
Exon 12 mutation	5 (28)
ECOG performance status	
0-1	17 (94)
2	1 (6)
Primary site	
Stomach	15 (82)
Small bowel	1 (6)
Rectum	1 (6)
Peritoneum	1 (6)
Metastatic site	
Liver	8 (50)
Peritoneum	5 (28)
Others	3 (19)

ECOG, Eastern Cooperative Oncology Group.

(PCR). The PCR products were sub-cloned using a TOPO TA cloning kit (K4500-01, Invitrogen, Carlsbad, CA) and sequenced twice using an ABI 3700 DNA analyzer (Applied Biosystems, Foster City, CA).

The chi-square test or Fisher exact test was used to assess the association between categorical variables, as appropriate. The probability of survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Progression-free survival (PFS) was defined as the time from the first dose of imatinib to disease progression or death from any cause. Overall survival (OS) was estimated as the time from the first dose of imatinib until death due to any cause, and censored at the last follow-up visit for patients who were still alive. Statistical analyses were performed using the SPSS ver. 18.0 (SPSS Inc., Chicago, IL). All tests were two-sided, with 5% serving as the level of significance.

Table 2. Summary of patient characteristics and treatment outcomes

Case No.	<i>PDGFRA</i> mutation	Primary site	Disease setting	Response to imatinib	PFS on imatinib (mo)	PFS on imatinib dose escalation (mo)	PFS on 2nd-line sunitinib (mo)	OS (mo)
1	Exon 12 P567P	Stomach	Metastatic	PR	63.8	-	-	65.6
2	Exon 12 P567P	Small bowel	Metastatic	SD	14.1 (PD)	1.0 (PD)	6.4 (PD)	46.9 (dead)
3	Exon 18 Del I843	Stomach	Localized	PR	10.1	-	-	63.8
4	Exon 12 P567P	Rectum	Metastatic	SD	24.8 (PD)	1.5 (PD)	20.0	59.8 (dead ^a)
5	Exon 18 Del D842	Stomach	Recurrent	PR	25.2 (PD)	5.7 (PD)	7.3 (PD)	51.2 (dead)
6	Exon 12 Del R560	Stomach	Metastatic	NE	50.9	-	-	53.4
7	Exon 12 V516D	Stomach	Metastatic	NE	44.4	-	-	45.8
8	Exon 18 Del IMHD843-846	Stomach	Recurrent	PR	3.9	-	-	3.9
9	Exon 18 Del IMHD843-846	Stomach	Metastatic	PR	29.5 (PD)	-	-	46.3
10	Exon 18 D842V	Stomach	Metastatic	PD	4.2 (PD)	-	14.3 (PD)	25.2 (dead)
11	Exon 18 D842V	Stomach	Metastatic	NE	2.7	-	-	32.5
12	Exon 18 D842V	Stomach	Localized	SD	1.4	-	-	28.6
13	Exon 18 D842V	Stomach	Recurrent	NE	0.2 (PD)	-	0.5 (PD)	2.6 (dead)
14	Exon 18 D842V	Stomach	Metastatic	PD	2.6 (PD)	0.7 (PD)	14.6 (PD)	23.8
15	Exon 18 D842V	Peritoneum	Recurrent	SD	3.8 (PD)	4.4 (PD)	1.9 (PD)	24.9
16	Exon 18 D842V	Stomach	Metastatic	NE	0.4	-	-	2.8
17	Exon 18 D842V	Stomach	Recurrent	NE	3.9 (PD)	-	0.7 (PD)	8.3 (dead)
18	Exon 18 D842V	Stomach	Recurrent	PD	0.8 (PD)	-	4.0 (PD)	18.7 (dead)

PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; NE, not evaluable; PD, progressive disease. ^aCause of death was pneumonia which was not disease-related.

Results

1. Patient characteristics

A total of 823 patients were genotyped for *KIT* and *PDGFRA*. *PDGFRA* mutations were detected in 35 patients (4%), and 19 patients (2%) received imatinib as first-line therapy for advanced disease. After exclusion of one patient who had received adjuvant imatinib prior to the use of imatinib for recurrent disease, 18 patients were analyzed to estimate the sensitivity of *PDGFRA*-mutant GISTs to imatinib. The patients' baseline characteristics are shown in Table 1. The patients' median age at the start of imatinib therapy was 58 years (range, 31 to 74 years) and 11 patients (61%) were male. Most patients in our series (n=17, 94%) were *KIT* expression-positive by immunohistochemistry; however, weak and focal expression was noted in three cases (17%) and one case (6%), respectively. Nine patients (50%) had exon 18 D842V substitution and four patients (22%) had non-D842V exon 18 mutations. Five patients (28%) had exon 12 mutations. Detailed clinical information of all patients is summarized in Table 2.

2. Efficacy of imatinib as first-line therapy

The responses to imatinib in patients with *PDGFRA*-mutant GISTs are summarized in Table 3. Twelve patients (67%) were available for response assessment; four had no measurable lesion after surgical resection and two were lost to follow-up before the first response evaluation. None of the patients showed a complete response; five patients (42%) showed a partial response and three patients (25%) showed stable disease. None of the five patients with the D842V mutation achieved an objective response, whereas five of seven patients (71%) with non-D842V *PDGFRA* mutations showed a partial response (p=0.03). With a median follow-up period of 32.5 months (range, 2.8 to 65.6 months) in surviving patients, the median PFS and OS was 24.8 months (95% confidence interval [CI], 0.0 to 57.2) and 51.2 months (95% CI, 37.1 to 65.3), respectively. Patients with D842V-mutant GISTs had significantly shorter median PFS than those with non-D842V *PDGFRA*-mutant GISTs: 3.8 months (95% CI, 1.4 to 6.3) vs. 29.5 months (95% CI, 18.3 to 40.7) (p < 0.001) (Fig. 1). In addition, patients with D842V-mutant GISTs showed inferior OS compared to those with non-D842V *PDGFRA*-mutant GISTs (median, 25.2 months; 95% CI, 12.7 to 37.8 vs. median, 59.8 months; 95% CI, 43.0 to 76.5; p=0.02).

Table 3. Response to first-line imatinib

Response	Type of mutation			Overall
	D842V exon 18	Non-D842V exon 18	Exon 12	
Complete response	0	0	0	0
Partial response	0	4 (100)	1 (33)	5 (42)
Stable disease	1 (20)	0	2 (67)	3 (25)
Progressive disease	4 (80)	0	0	4 (33)

Values are presented as number (%). Six patients (two with D842V substitution and two with exon 12 mutations) were non-evaluable because of non-measurable lesions in four patients and early loss to follow-up in two patients.




Fig. 1. Progression-free survival (A) with first-line imatinib and overall survival (B) according to the type of *PDGFRA* mutation.

3. Outcomes with second-line therapy

Among ten patients with documented tumor progression on a standard dose of imatinib, five (three with non-D842V mutations and two with D842V substitution) received an increased dose of imatinib (600 mg/day or 800 mg/day). None of the patients showed an objective response and the median PFS was 1.5 months (95% CI, 0.5 to 2.5). Nine patients were treated with sunitinib after failure of imatinib (three had non-D842V mutations and six had D842V substitution). The responses to second-line sunitinib treatment in the overall population and according to mutation type are summarized in Table 4. None of the patients achieved an objective response. The median PFS with second-line therapy was 6.4 months (95% CI, 0.0 to 13.5) (Fig. 2). Patients with the D842V substitution tended to show poorer PFS than those with non-D842V *PDGFRA* mutations (median, 1.9 months; 95% CI, 0.0

to 5.9 vs. median, 7.3 months; 95% CI, 5.9 to 8.8; $p=0.26$), although the difference did not reach statistical significance.

Discussion

In management of unresectable or metastatic advanced GISTs, tumor genotype, particularly *KIT* exon mutations, has been regarded as an important predictive factor for the efficacy of imatinib. However, because *PDGFRA*-mutant GISTs are generally indolent and localized with a low-risk of recurrence [1-4], data on the response to imatinib in patients with advanced disease harboring these specific mutations have been mainly based on a few cases. A relatively large European retrospective study recently reported that imatinib has

Table 4. Response to second-line sunitinib

Response	Type of mutation			
	D842V exon 18	Non-D842V exon 18	Exon 12	Overall
Complete response	0	0	0	0
Partial response	0	0	0	0
Stable disease	3 (50)	1 (100)	2 (100)	6 (67)
Progressive disease	3 (50)	0	0	3 (33)

Values are presented as number (%).




Fig. 2. Progression-free survival with second-line sunitinib treatment after failure of imatinib.

little efficacy in the subgroup of patients with *PDGFRA* exon 18 D842V substitution, while other types of *PDGFRA* mutations appear to be sensitive to imatinib; however, additional data were still needed in order to improve our understanding of imatinib sensitivity in this group of patients [13]. The results of the current study are in agreement with those of previous studies, and could add to the evidence in regard to sensitivity to imatinib in *PDGFRA*-mutant GISTs.

In our series, *PDGFRA* mutations were detected in 4% of patients with GISTs genotyped for *KIT* and *PDGFRA*. These results are similar to those of two Western phase III trials [9,10] and a Korean retrospective study [16] of first-line imatinib treatment, which reported frequency of 2%-5%. However, our results differ significantly from those of previous population-based studies reporting 14%-16% as the frequency of *PDGFRA* mutations [2-4]. The large discrepancies in the results between population-based studies and clinical

trials of imatinib could be associated with the proportion of patients with localized disease among the whole study population, considering that *PDGFRA*-mutant GISTs are more frequent in localized disease than in metastatic disease [2-4]. Most patients in our registry were referred from other hospitals following diagnosis. Therefore, compared with population-based studies, it is more likely that our registry included patients with high-risk or advanced disease. This might explain why the frequency of *PDGFRA* mutations in our study was similar to that reported in clinical trials for advanced GISTs rather than population-based studies. Most *PDGFRA* mutations occurred in gastric GISTs (88%), and exon 18 D842V substitution (50%) was the most common type of *PDGFRA* mutation, as previously reported [1]. *PDGFRA* mutations were more common in *KIT*-negative GISTs [17]. However, most of our patients (17 of 18, 94%) had *KIT*-positive GISTs by immunohistochemistry, although 23% had weak or focal expression. Our results are consistent with those of the European study, which included a large patient cohort, and reported that 85% of patients were *KIT*-positive [15]. These findings suggest that *KIT* is overexpressed in most *PDGFRA*-mutant GISTs [15] and, although mutations of *KIT* and *PDGFRA* are mutually exclusive in GISTs, expression of those proteins is not [18].

Consistent with previous preclinical and clinical studies [9-13], our results showed that GISTs with the D842V mutation are primarily resistant to imatinib. Patients with D842V mutant GISTs showed no objective response to first-line imatinib and most of them progressed within 6 months of treatment. The median PFS of this group was 3.8 months, consistent with the results of a previous retrospective study (2.8 months) [13]. This inherent resistance of D842V-mutated GISTs to imatinib can be explained as this substitution results in a change in the kinase activation loop that induces the protein conformation to favor the active conformation, considering that imatinib can only bind to the inactive conformation of *PDGFRA* [19]. Sustained tumor control with imatinib was previously reported in some patients [9,13];

however, there is no biomarker to differentiate patients who might potentially benefit from imatinib treatment from those who would not. Because of the lack of efficacy of imatinib in patients with this mutation, mutational analysis should be performed to exclude GIST patients with the *PDGFRA* D842V substitution before administration of adjuvant imatinib after curative surgical resection or neoadjuvant imatinib for organ preservation or marginally resectable disease [20].

For patients with metastatic or unresectable GISTs with D842V mutation, a phase 2 study of crenolanib, a novel platelet-derived growth factor receptor inhibitor, is ongoing for this subgroup of patients based on the promising preclinical activity (NCT01243346) [21]; however, there is no currently approved drug with activity against the D842V mutation [12,22]. Therefore, these patients should be encouraged to participate in clinical trials for investigational drugs with potential activity against this mutation. If such drugs are not an option, imatinib therapy should be tried for the potential chance of achieving disease control.

In addition to the D842V substitution, in-frame deletion, deletion/insertion and substitutions in *PDGFRA* exon 18, and deletions, substitutions and duplications in exon 12 have been previously identified [1]. Although rare, substitutions in exon 4 and 14 have also been reported [1,2,13]. In the current study, patients with non-D842V mutant GISTs had various mutations in exons 18 and 12. In line with previous *in vitro* studies investigating the sensitivity of imatinib against non-D842V *PDGFRA* mutations [1,12], first-line imatinib was effective in our GIST patients with non-D842V *PDGFRA* mutations, who showed a median PFS of 29.5 months. This finding is consistent with the results of a previous analysis of non-D842V *PDGFRA*-mutant GISTs, which showed association with superior PFS and OS compared to D842V mutant GISTs [13]. Compared with the outcomes of patients with different genotypes in previous studies, PFS of our patients with non-D842V *PDGFRA* mutations was similar to that previously reported for patients with *KIT* exon 11 mutations in Western trials [9-11], and those with *KIT* exon 9 mutations in a Korean multicenter

retrospective analysis [16], suggesting that sensitivity to imatinib in this patient subgroup may be similar to that of patients with *KIT* mutations. In the current study, one patient with Del D842 showed long-term disease control with partial response, and progressed after approximately 2 years of imatinib therapy. A previous study that included two patients with Del D842 reported that one patient showed a long-term response [13]. Taken together with the *in vitro* activity of imatinib in GISTs with D842-involving deletions [12,23], these findings suggest that the nature of the mutation, in addition to its location, plays an important role in the sensitivity to imatinib, in addition to its location [13].

The current study had several limitations associated with its retrospective nature and the small sample size. However, *PDGFRA* mutations are infrequent, particularly in advanced disease, and few studies have investigated the therapeutic outcomes of this subgroup. Therefore, our results may provide guidance in the treatment of patients with GISTs harboring *PDGFRA* mutations.

Conclusion

We showed that imatinib is active against non-D842V *PDGFRA*-mutant GISTs, whereas GISTs harboring the D842V mutation are primarily resistant to imatinib. Considering that no approved drug has shown efficacy against D842V-mutant GISTs, enrollment in clinical trials should be encouraged in this group of patients, especially if investigational drugs with *in vitro* activity are identified.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

References

1. Lasota J, Miettinen M. Clinical significance of oncogenic *KIT* and *PDGFRA* mutations in gastrointestinal stromal tumours. *Histopathology*. 2008;53:245-66.
2. Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, et al. Prognostic value of *KIT*/*PDGFRA* mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. *Ann Oncol*. 2012;23:353-60.
3. Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, et al. Frequencies of *KIT* and *PDGFRA* mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. *Med Oncol*. 2012;29:1765-72.
4. Cassier PA, Ducimetiere F, Lurkin A, Ranchere-Vince D, Scoazec JY, Bringuier PP, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in

- Rhone Alpes region: incidence and molecular distribution of GIST in a European region. *Br J Cancer*. 2010;103:165-70.
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med*. 2002;347:472-80.
 6. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet*. 2004;364:1127-34.
 7. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol*. 2008;26:626-32.
 8. Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, et al. A prospective, multicenter, phase 2 study of imatinib mesylate in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. *Oncology*. 2009;76:326-32.
 9. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *J Clin Oncol*. 2008;26:5360-7.
 10. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. *Eur J Cancer*. 2006;42:1093-103.
 11. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *J Clin Oncol*. 2010;28:1247-53.
 12. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol*. 2005;23:5357-64.
 13. Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. *Clin Cancer Res*. 2012;18:4458-64.
 14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*. 2000;92:205-16.
 15. Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, et al. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. *Jpn J Clin Oncol*. 2006;36:17-24.
 16. Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, et al. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. *Acta Oncol*. 2012;51:528-36.
 17. Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. *Oncogene*. 2004;23:7780-90.
 18. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol*. 2005;29:52-68.
 19. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. *Clin Cancer Res*. 2009;15:7510-8.
 20. Kang YK, Kang HJ, Kim KM, Sohn T, Choi D, Ryu MH, et al. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. *Cancer Res Treat*. 2012;44:85-96.
 21. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res*. 2012;18:4375-84.
 22. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol*. 2008;26:5352-9.
 23. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRA D842V mutation. *Clin Cancer Res*. 2008;14:5749-58.